Pharmacological studies of the opioids, mood stabilizer and dopaminergic drugs on pilocarpine-induced seizures and status epilepticus.
This work was designed to study the influence of drugs during seizures and status epilepticus (SE) induced by pilocarpine and mortality in adult rats. Morphine (0.1 and 0.2 mg/kg), SCH 23390 (0.1 and 0.2 mg/kg), haloperidol (5 and 10mg/kg) and lithium (30 and 60 mg/kg) were administered intraperitoneally (i.p.), 30 min before to pilocarpine (400 mg/kg, s.c.). The animals were observed (24 h) to determine: number of peripheral cholinergic signs, tremors, stereotyped movements, seizures, SE, latency to first seizure and number of deaths after pilocarpine treatment. Morphine and haloperidol had proconvulsant effects in both doses tested. Smaller and higher doses of these drugs no protected and increased pilocarpine-induced seizures, SE and/or mortality. SCH 23390 protected against seizures, increased the latency to first seizure and reduced the mortality of the animals treated with pilocarpine Theses results suggest that dopamine receptor system receptor subtypes exert opposite functions on the regulation of convulsive activity. The morphine is proconvulsant in lower doses. The opioids in high doses tested exert an action proconvulsant during the establishment of epileptic activity induce by pilocarpine. The lithium no protected the animals against seizures induced by pilocarpine and is used which a model of epilepsy associated with lower doses of pilocarpine in several studies, suggesting absence of the effect anticonvulsants in rodents.
Freitas
R M
RM
Department of Physiology and Pharmacology, Laboratory of Neuropharmacology, School of Medicine, Federal University of Ceara, Rua Cel. Nunes de Melo 1127, Fortaleza 60431-970, CE, Brazil. rivmendes@bol.com.br
Vasconcelos
S M M
SM
Sousa
F C F
FC
Viana
G S B
GS
Fonteles
M M F
MM
D000701:Analgesics, Opioid / Q000627:therapeutic use; D000818:Animals; D018692:Antimanic Agents / Q000627:therapeutic use; D018492:Dopamine Antagonists / Q000627:therapeutic use; D006220:Haloperidol / Q000627:therapeutic use; D018021:Lithium Chloride / Q000627:therapeutic use; D008297:Male; D009020:Morphine / Q000627:therapeutic use; D018721:Muscarinic Agonists / Q000494:pharmacology; D010862:Pilocarpine / Q000494:pharmacology*; D051381:Rats; D012640:Seizures / Q000139:chemically induced* / Q000188:drug therapy* / Q000401:mortality; D013226:Status Epilepticus / Q000139:chemically induced* / Q000188:drug therapy* / Q000401:mortality
D000701:Analgesics, Opioid; D018692:Antimanic Agents; D018492:Dopamine Antagonists; D018721:Muscarinic Agonists; D010862:Pilocarpine; D009020:Morphine; D018021:Lithium Chloride; D006220:Haloperidol